Publikationer (Jan Hillert)

Utvalda publikationer från Jan Hillerts forskargrupp

 

  1. Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers. Forsberg L, Spelman T, Klyve P, Manouchehrinia A, Ramanujam R, Mouresan E, Drahota J, Horakova D, Joensen H, Pontieri L, Magyari M, Ellenberger D, Stahmann A, Rodgers J, Witts J, Middleton R, Nicholas R, Bezlyak V, Adlard N, Hach T, Lines C, Vukusic S, Soilu-Hänninen M, van der Walt A, Butzkueven H, Iaffaldano P, Trojano M, Glaser A, Hillert J; SPMS Research Collaboration Network.Mult Scler J Exp Transl Clin. 2023 Feb 16;9(1):20552173231153557. doi: 10.1177/20552173231153557. eCollection 2023 Jan-Mar.PMID: 36816812

 

  1. Association between early treatment of multiple sclerosis and patient-reported outcomes: a nationwide observational cohort study. He A, Spelman T, Manouchehrinia A, Ciccarelli O, Hillert J, McKay K.J Neurol Neurosurg Psychiatry. 2023 Apr;94(4):284-289. doi: 10.1136/jnnp-2022-330169. Epub 2022 Dec 7.PMID: 36600595

 

  1. Trajectories of disease-modifying therapies and associated sickness absence and disability pension among 1923 people with multiple sclerosis in Sweden. Teni FS, Machado A, Murley C, He A, Fink K, Gyllensten H, Glaser A, Alexanderson K, Hillert J, Friberg E. Mult Scler Relat Disord. 2023 Jan;69:104456. doi: 10.1016/j.msard.2022.104456. Epub 2022 Dec 9.PMID: 36529068

 

  1. Reduction in Cognitive Processing Speed Surrounding Multiple Sclerosis Relapse. McKay KA, Bedri SK, Manouchehrinia A, Stawiarz L, Olsson T, Hillert J, Fink K. Ann Neurol. 2022 Mar;91(3):417-423. doi: 10.1002/ana.26301. Epub 2022 Jan 24.PMID: 34984719

 

  1. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis Data From 2 Different National Strategies. Spelman T, Magyari M, Piehl F, Svenningsson A, Rasmussen PV, Kant M, Sellebjerg F, Joensen H, Hillert J, Lycke J. JAMA NEUROLOGY 2021 78;10 1197-1204

 

  1. Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry. Spelman T, Forsberg L, McKay K, Glaser A, Hillert J. Mult Scler. 2022 Jun;28(7):1051-1059. doi: 10.1177/13524585211026272. Epub 2021 Jul 2.PMID: 34212816

 

  1. Long-term Socioeconomic Outcomes Associated With Pediatric-Onset Multiple Sclerosis. McKay KA, Friberg E, Razaz N, Alexanderson K, Hillert J. JAMA Neurol. 2021 Apr 1;78(4):478-482. doi: 10.1001/jamaneurol.2020.5520.PMID: 33616605

 

  1. Accurate classification of secondary progression in multiple sclerosis using a decision tree. Ramanujam R, Zhu F, Fink K, Karrenbauer VD, Lorscheider J, Benkert P, Kingwell E, Tremlett H, Hillert J, Manouchehrinia A; BeAMS Study group. Mult Scler. 2021 Jul;27(8):1240-1249. doi: 10.1177/1352458520975323. Epub 2020 Dec 2.PMID: 33263261

 

  1. Long-term disability progression of pediatric-onset multiple sclerosis. McKay KA, Hillert J, Manouchehrinia A. Neurology. 2019 Jun 11;92(24):e2764-e2773. doi: 10.1212/WNL.0000000000007647. Epub 2019 May 15.PMID: 31092624

 

  1. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden. Beiki O, Frumento P, Bottai M, Manouchehrinia A, Hillert J. JAMA Neurol. 2019 Jun 1;76(6):665-671. doi: 10.1001/jamaneurol.2019.0330.PMID: 30882868

 

 

  1. Age Related Multiple Sclerosis Severity Score: Disability ranked by age. Manouchehrinia A, Westerlind H, Kingwell E, Zhu F, Carruthers R, Ramanujam R, Ban M, Glaser A, Sawcer S, Tremlett H, Hillert J..  Mult Scler. 2017 Dec;23(14):1938-1946.

 

  1. Importance of early treatment initiation in the clinical course of multiple sclerosis. Kavaliunas A, Manouchehrinia A, Stawiarz L, Ramanujam R, Agholme J, Hedström AK, Beiki O, Glaser A, Hillert J. Mult Scler. 2017 Aug;23(9):1233-1240.

 

  1. Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. Hillert J, Magyari M, Sorensen PS, Butzkueven H, Van Der Welt A, Vukusic S, Trojano M, Iaffaldano P, Pellegrini F, Hyde RB, Stawiarz L, Manouchehrinia A, Spelman T, Danish MS Registry, Italian MS Registry, Observ Francais Sclerose Plaques, MSBase Study Grp, Swedish MS Registry. FRONTIERS IN NEUROLOGY 2021 12; 647811-

 

  1. Effect of Smoking Cessation on Multiple Sclerosis Prognosis. Ramanujam R, Hedström AK, Manouchehrinia A, Alfredsson L, Olsson T, Bottai M, Hillert J. JAMA Neurol. 2015 Oct;72(10):1117-23.

 

  1. The Swedish MS registry – clinical support tool and scientific resource. Hillert J, Stawiarz L. Acta Neurol Scand. 2015;132(199):11-9.

 

 

A multiple sclerosis disease progression measure based on cumulative disability.
Manouchehrinia A, Kingwell E, Zhu F, Tremlett H, Hillert J, Ramanujam R
Mult Scler 2021 Jan;():1352458520988632

Cerebrospinal fluid oligoclonal immunoglobulin gamma bands and long-term disability progression in multiple sclerosis: a retrospective cohort study.
Karrenbauer VD, Bedri SK, Hillert J, Manouchehrinia A
Sci Rep 2021 07;11(1):14987

Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network.
Iaffaldano P, Lucisano G, Butzkueven H, Hillert J, Hyde R, Koch-Henriksen N, Magyari M, Pellegrini F, Spelman T, Sørensen PS, Vukusic S, Trojano M
Mult Scler 2021 Sep;27(10):1543-1555

Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis.
Hedström AK, Hillert J, Olsson T, Alfredsson L
J Neurol Neurosurg Psychiatry 2021 Oct;92(10):1096-1102

Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network.
Hillert J, Magyari M, Soelberg Sørensen P, Butzkueven H, Van Der Welt A, Vukusic S, Trojano M, Iaffaldano P, Pellegrini F, Hyde R, Stawiarz L, Manouchehrinia A, Spelman T
Front Neurol 2021 ;12():647811

Determinants of quality of life in pediatric- and adult-onset multiple sclerosis.
McKay KA, Ernstsson O, Manouchehrinia A, Olsson T, Hillert J
Neurology 2020 03;94(9):e932-e941

Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis.
Dunn N, Fogdell-Hahn A, Hillert J, Spelman T
Front Immunol 2020 ;11():583560

Socioeconomic status and multiple sclerosis outcome.
Hillert J
Nat Rev Neurol 2020 04;16(4):191-192

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, Sharmin S, Horakova D, Kubala Havrdova E, Spelman T, Izquierdo G, Eichau S, Trojano M, Lugaresi A, Hupperts R, Sola P, Ferraro D, Lycke J, Grand'Maison F, Prat A, Girard M, Duquette P, Larochelle C, Svenningsson A, Petersen T, Grammond P, Granella F, Van Pesch V, Bergamaschi R, McGuigan C, Coles A, Hillert J, Piehl F, Butzkueven H, Kalincik T,
Lancet Neurol 2020 04;19(4):307-316

Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
Beiki O, Frumento P, Bottai M, Manouchehrinia A, Hillert J
JAMA Neurol 2019 06;76(6):665-671
 

För komplett publikationslista, se Google Scholar eller PubMed

JH
Innehållsgranskare:
Jan Hillert
Nilla Karlsson
2023-05-08